Administering MSCs after stroke improves functional neurologic outcomes, reduces infarct sizes, increases survival of neurons, and normalizes biochemical parameters through modulating ER stress-mediated apoptosis through the BDNF/TrkB signaling pathway. Here, NTRK2 is linked to Stroke.